News and Trends 30 Jun 2022
NRG Therapeutics selects Domainex for project aimed at finding candidate for neurogenerative disorders
A neuroscience company targeting mitochondrial dysfunction has teamed up with an organization developing small molecule disease-modifying medicines for the treatment for chronic neurogenerative disorders. Domainex, an integrated medicines research services partner has been chosen by neuroscience company, NRG Therapeutics, and will be providing fully integrated lead optimization services including assay biology and medicinal computational chemistry. […]